Laboratory Corporation of America Holdings

Equities

LH

US50540R4092

Healthcare Facilities & Services

Market Closed - Nyse 04:00:02 2024-04-16 pm EDT 5-day change 1st Jan Change
201.9 USD -0.68% Intraday chart for Laboratory Corporation of America Holdings -3.87% -11.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Labcorp Introduces Test for Early Detection of Neurodegenerative Diseases MT
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw CI
Labcorp Keeps Quarterly Dividend at $0.72 Per Share, Payable June 12 to Stockholders of Record May 28 MT
Labcorp Declares Quarterly Dividend, Payable on June 12, 2024 CI
Sector Update: Health Care Stocks Slump Wednesday Afternoon MT
Labcorp Says US FDA Granted Emergency Use Authorization for Mpox Home Collection Kit MT
Labcorp Gets Emergency Authorization from FDA for Home Kit to Detect Monkeypox DJ
Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit CI
Laboratory Corp of America Expands Precision Oncology Portfolio MT
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs CI
Labcorp Launches Labcorp Plasma Detect? Extending Leadership into Molecular Residual Disease Clinical Research CI
Laboratory Corporation Receives a Shareholder Proposal from People for the Ethical Treatment of Animals CI
Laboratory Corporation Receives a Shareholder Proposal from Tara Health Foundation CI
Laboratory Corporation Receives a Shareholder Proposal from John Chevedden CI
Laboratory Corp Of America Holdings Insider Sold Shares Worth $760,515, According to a Recent SEC Filing MT
Laboratory Corp Of America Holdings Insider Sold Shares Worth $1,407,387, According to a Recent SEC Filing MT
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research CI
Labcorp Expands Investment, Collaboration Pact with Xcell Biosciences MT
Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration with Labcorp CI
Prelude Network Announces Expansion of Partnership with Labcorp to Serve as Its Preferred Genetic Carrier Screening Lab CI
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets MT
Laboratory Corporation of America Holdings (NYSE:LH) entered into an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million. CI
North American Morning Briefing : Markets Steady -2- DJ
Argus Upgrades Laboratory Corp of America Holdings to Buy From Hold, Price Target is $250 MT
Laboratory Corp of America Launches PTau217 Diagnostic Test for Alzheimer's Disease MT
Chart Laboratory Corporation of America Holdings
More charts
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows: - clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services; - development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies. Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
203.3 USD
Average target price
244.1 USD
Spread / Average Target
+20.08%
Consensus
  1. Stock Market
  2. Equities
  3. LH Stock
  4. News Laboratory Corporation of America Holdings
  5. Laboratory Corp of America Posts Lower Q2 Adjusted Earnings, Revenue; Company to Spin Off Clinical Development Business